Skip to main content

Table 2 Clinical evolution (maximum or minimum values) of the original-eligible population and weighted population while treated with HFNO

From: Awake prone positioning does not reduce the risk of intubation in COVID-19 treated with high-flow nasal oxygen therapy: a multicenter, adjusted cohort study

° Original sample Weighted sample
HFNO (n = 133) HFNO + awake-PP (n = 51) P value HFNO 68.4% HFNO + awake-PP 31.6% P value
Scores
 Non-respiratory SOFA 4.0 [4.00–5.00]/125 4.0 [4.00–5.00]/46 0.25 4.8 5.0 0.62
Vital signs
 Temperature, °C 37.2 [36.50–38.00]/141 37.1 [36.60–37.80]/54 0.80 37.2 37.3 0.53
 Mean arterial pressure, mmHg 77.0 [70.50–83.83]/140 76.2 [68.00–84.00]/54 0.59 77.8 73.4 0.053
 Heart rate, bpm 85.0 [75.00–96.00]/141 85.0 [79.00–100.00]/54 0.62 87.2 91.4 0.26
 SpO2, % 89.0 [86.00–92.00]/141 88.0 [84.00–90.00]/54 0.11 88.8 87.6 0.21
 Respiratory rate minimum, bpm 21.0 [18.00–24.00]/141 19.0 [16.00–23.00]/54 0.004 20.8 19.7 0.23
 Respiratory rate maximum, bpm 27.0 [24.00–32.00]/141 27.0 [23.00–30.00]/54 0.49 27.7 27.1 0.64
Arterial blood gas
 PaO2/FiO2 92.5 [77.00–125.50]/128 103.0 [80.00–125.00]/53 0.45 109.7 113.8 0.67
 PaCO2, mmHg 39.9 [35.50–48.00]/131 41.2 [36.20–46.00]/53 0.56 44.8 42.4 0.29
Laboratory findings
 Ferritin, ng/mL 1279.0 [694.00–2151.00]/107 1499.0 [809.00–2425.00]/45 0.45 1817.2 1955.0 0.75
 D-Dimer, ng/mL 1681.0 [820.00–4200.00]/122 1590.0 [1030.00–3200.00]/50 0.98 2799.7 2624.9 0.76
 CRP, mg/dL 21.3 [9.32–33.19]/132 22.7 [8.66–146.14]/53 0.23 62.4 62.6 0.98
 Lymphocytes, μL 0.47 [0.30–0.74]/135 0.44 [0.30–0.60]/53 0.31 0.56 0.42 0.021
 IL-6, pg/mL 177.0 [42.70–415.90]/17 87.5 [24.00–301.00]/14 0.34 832.7 221.6 0.33
 LDH, U/L 429.0 [345.00–561.00]/125 449.0 [352.00–602.00]/51 0.51 451.2 490.3 0.29
 Leukocytes, 103/μL 8.3 [5.80–12.00]/122 7.7 [5.21–12.33]/51 0.75 9.7 9.0 0.60
 Procalcitonin, ng/mL 0.22 [0.11–0.57]/114 0.20 [0.09–0.34]/45 0.57 1.24 0.34 0.10
 Platelets, 1000/mm3 319.0 [212.50–410.50]/136 303.0 [244.00–358.00]/53 0.64 330.6 329.7 0.97
 Bilirrubin, mg/dL 0.80 [0.50–1.10]/130 0.84 [0.60–1.18]/50 0.33 1.23 0.90 0.052
 ALT, U/L 66.0 [30.00–104.00]/135 52.0 [32.00–116.00]/53 0.82 85.2 105.6 0.35
 Creatinin, mg/dL 0.90 [0.70–1.18]/136 0.86 [0.75–1.02]/52 0.45 1.10 1.09 0.96
 Urea, mg/dL 42.0 [30.00–64.00]/91 39.5 [26.00–61.00]/50 0.44 52.0 42.7 0.12
 Troponin, ng/mL 11.8 [4.30–25.00]/89 9.6 [4.60–27.52]/39 0.69 18.8 9.3 0.27
 NTproBNP, pg/mL 335.5 [125.50–938.80]/20 303.1 [91.00–1019.00]/14 0.75 727.9 660.9 0.82
 Hematocrit, % 38.00 [34.70–42.00]/111 39.20 [36.00–42.50]/45 0.97 38.2 39.4 0.35
 Lactate, mmol/L 1.5 [1.16–2.10]/77 1.5 [1.20–2.10]/31 0.60 1.85 1.88 0.91
  1. Maximum or minimum values during the period of HFNO. Categorical variables are expressed as proportion, and continuous variables as median (IQR) for original-eligible population and percentage and mean for weighted population
  2. HFNO high-flow nasal oxygen therapy, SpO2 peripheral oxyhemoglobin saturation, SOFA Sequential Organ Failure Assessment, RCP C-reactive protein, IL interleukin, LDH lactate dehydrogenase, GPT glutamate pyruvate transaminase